---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038312"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:04:11.197823+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics Q2 core revenue rises 48% to $67M; raises FY2023 guidance to $260M

## Summary
- Total revenue $68M; core revenue $67M, up 48% YoY.
- GAAP net loss $11.2M ($0.38/share); Non-GAAP loss $2.4M ($0.08/share).
- Adjusted EBITDA loss $2.7M; cash flow from operations $9.7M.
- Raises full-year 2023 core revenue guidance to $260M, narrows expected loss.
- Cash, cash equivalents, and investments $846.8M as of June 30, 2023.

## SEC filing metadata
- accession: 0000950170-23-038312
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/0000950170-23-038312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/flgt-20230804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038312
- JSON: https://secwatch.observer/filing/0000950170-23-038312.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038312.txt

## Key facts
- Earnings Releases
  Fulgent Genetics, Inc. reported second quarter ended June 30, 2023 results: revenue $68 million, net income GAAP loss of $11.2 million, or $0.38 per share, EPS $0.38 per share. Guidance raised.
  - Period: second quarter ended June 30, 2023
  - Revenue: $68 million
  - Net income: GAAP loss of $11.2 million, or $0.38 per share
  - EPS: $0.38 per share
  - Guidance: raised
  - Result: reported results
  source text: X-99.1 Exhibit 99.1 Fulgent Reports Second Quarter 2023 Financial Results • Total Revenue of $68 million • Record Core Revenue of $67 million, growth of 48% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss EL MONTE, CA, August 4, 2023 — Fulgent Genetics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000095017023038312/0000950170-23-038312-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.